Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An adenoma or carcinoma of the pituitary gland that produces corticotropin.
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
14 publications have been identified in PubMed for ACTH-producing pituitary gland neoplasm. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (29%), and Clinical Trial Publication (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 50% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:56 PM UTC
Common questions about ACTH-producing pituitary gland neoplasm
Research summaries |
4 |
29% |
Clinical study results | 1 | 7% |
Laboratory research | 1 | 7% |
Disease patterns and progression | 1 | 7% |
Sah RK (2026). [PMID: 41497147](https://pubmed.ncbi.nlm.nih.gov/41497147/). *Ann Med Surg (Lond)*. [Case Report / Case Series]
Uysal S (2025). [PMID: 40049225](https://pubmed.ncbi.nlm.nih.gov/40049225/). *Horm Metab Res*. [Epidemiology / Natural History]
Kalasauskas D (2025). [PMID: 39883209](https://pubmed.ncbi.nlm.nih.gov/39883209/). *Neurosurg Rev*. [Case Report / Case Series]
Elenius H (2025). [PMID: 41130648](https://pubmed.ncbi.nlm.nih.gov/41130648/). *Endocrinol Metab Clin North Am*. [Review / Meta-Analysis]
Laffi A (2025). [PMID: 41282293](https://pubmed.ncbi.nlm.nih.gov/41282293/). *Front Endocrinol (Lausanne)*. [Clinical Trial Publication]
Ewert J (2025). [PMID: 39956106](https://pubmed.ncbi.nlm.nih.gov/39956106/). *Neuroendocrinology*. [Review / Meta-Analysis]
Mena E (2025). [PMID: 40447542](https://pubmed.ncbi.nlm.nih.gov/40447542/). *Semin Nucl Med*. [Review / Meta-Analysis]
Aljabrain F (2025). [PMID: 40400805](https://pubmed.ncbi.nlm.nih.gov/40400805/). *Cureus*. [Case Report / Case Series]
Brown BM (2025). [PMID: 41035790](https://pubmed.ncbi.nlm.nih.gov/41035790/). *JCEM Case Rep*. [Case Report / Case Series]
Nakatsuji M (2025). [PMID: 40467468](https://pubmed.ncbi.nlm.nih.gov/40467468/). *Endocr J*. [Review / Meta-Analysis]
AI-curated news mentioning ACTH-producing pituitary gland neoplasm
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.